Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis

BackgroundAtopic dermatitis (AD) and psoriasis represent contrasting poles of the TH1 versus TH2 paradigm. Both diseases have been associated with increased numbers of dendritic cells (DCs) in the skin, but the similarities and differences in DC populations need to be established.ObjectiveWe aimed to characterize the specific DC subsets, as well as chemokine and cytokine environment in chronic AD compared with psoriasis.MethodsSkin biopsies were obtained from patients with acute exacerbation of chronic AD (n = 18), psoriasis (n = 15), and healthy volunteers (n = 15) for microarray analysis, RT-PCR, immunohistochemistry, and double-label immunofluorescence.ResultsMyeloid DCs upregulate CCL17 and CCL18 in AD, as opposed to TNF-α and inducible nitric oxide synthase (iNOS) in psoriasis. In our study, we identified cells phenotypically identical to the inflammatory dendritic epidermal cells in the dermis in both diseases, although to a lesser extent in psoriasis. We found substantially higher numbers of dermal CCL22 producing plasmacytoid DCs in AD. The thymic stromal lymphopoietin receptor showed significantly higher expression in AD, whereas the thymic stromal lymphopoietin ligand was upregulated more in psoriasis.ConclusionThere are major differences in myeloid and plasmacytoid subsets of cutaneous DCs and the chemokine/cytokine environment between AD and psoriasis. Distinct subsets within the CD11c+ population may influence polarization through the production of regulatory mediators, including iNOS, TNF, CCL17, and CCL18. Plasmacytoid DCs may also influence TH2 polarization, having a more important role in AD than previously appreciated.Clinical implicationsDermal inflammatory dendritic cells in AD and TNF and iNOS–producing DCs in psoriasis, and/or their regulatory products, may be potential targets for future therapeutic interventions.